AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results From the ATTRibute-CM Study
Trial in peopleInterventions
Papers by Richard Wright
1 result